Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. (3-(2-dimethylamino)ethyl)indol-4-ol
2. Psilocin Hydrochloride
3. Psilocin Tartrate (1:1)
1. Psilocine
2. 4-hydroxy-n,n-dimethyltryptamine
3. 520-53-6
4. Psilotsin
5. Psilocyn
6. 3-[2-(dimethylamino)ethyl]-1h-indol-4-ol
7. 3-(2-(dimethylamino)ethyl)indol-4-ol
8. N,n-dimethyl-4-hydroxytryptamine
9. 3-(2-(dimethylamino)ethyl)-1h-indol-4-ol
10. Cms88kuw0g
11. 4-ho-dmt
12. Chembl65547
13. Chebi:8613
14. Ncgc00247728-01
15. 1h-indol-4-ol, 3-[2-(dimethylamino)ethyl]-
16. 3-[2-(dimethylamino)ethyl]-1~{h}-indol-4-ol
17. Indol-4-ol, 3-(2-(dimethylamino)ethyl)-
18. Indol-4-ol, 3-[2-(dimethylamino)ethyl]-
19. Cx-59
20. Einecs 208-296-5
21. Unii-cms88kuw0g
22. Brn 0160503
23. Dea No. 7438
24. 91q
25. Psilocin [mi]
26. Psilocin [mart.]
27. Psilocin [who-dd]
28. 4-oh-dmt
29. Magic Mushrooms (salt/mix)
30. Dsstox_cid_28825
31. Dsstox_rid_83094
32. Dsstox_gsid_48899
33. 5-22-12-00014 (beilstein Handbook Reference)
34. Schembl194899
35. Psilocin/psilocybin (salt/mix)
36. Zinc2001
37. Dtxsid5048899
38. Gtpl11291
39. Spciygntamctro-uhfffaoysa-
40. Cx 59
41. Tox21_112894
42. Bdbm50081701
43. Akos022505992
44. En-0002
45. 3-[2-(dimethylamino)ethyl]-indol-4-ol
46. Cas-520-53-6
47. 3-[2-(dimethylamino)ethyl]-1h-indol-4-ol #
48. C08312
49. P-7800
50. 4-hydroxy-n,n-dimethyltryptamine Psilocin
51. L000675
52. Q409150
53. Psilocin, Vial Of 5 Mg, Certified Reference Material
54. Psilocin Solution, 100 Mug/ml In Methanol, Drug Standard
55. Psilocin Solution, 1.0 Mg/ml In Acetonitrile, Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 204.27 g/mol |
|---|---|
| Molecular Formula | C12H16N2O |
| XLogP3 | 2.1 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 3 |
| Exact Mass | 204.126263138 g/mol |
| Monoisotopic Mass | 204.126263138 g/mol |
| Topological Polar Surface Area | 39.3 Ų |
| Heavy Atom Count | 15 |
| Formal Charge | 0 |
| Complexity | 208 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Hallucinogens
Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)
Psilocin has known human metabolites that include (2S,3S,4S,5R)-6-[[3-[2-(dimethylamino)ethyl]-1H-indol-4-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ELE-101, a patent-protected IV formulation of psilocin, has been designed to provide consistent and controllable drug delivery in patients with major depressive disorder.
Lead Product(s): Psilocin,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 20, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Atai's ELE-101 Phase 1/2a Trial Update for Depression
Details : ELE-101, a patent-protected IV formulation of psilocin, has been designed to provide consistent and controllable drug delivery in patients with major depressive disorder.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 20, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The proceeds of the Private placement will be used to advance Tryp's research and development program TRYP-0082 (psilocybin) and for general working capital purposes.
Lead Product(s): Psilocin,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Alto Capital Limited
Deal Size: $0.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 11, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Alto Capital Limited
Deal Size : $0.1 million
Deal Type : Private Placement
Details : The proceeds of the Private placement will be used to advance Tryp's research and development program TRYP-0082 (psilocybin) and for general working capital purposes.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
October 11, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Psilocin is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Psilocin,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Pharmaceutical Research Unit, Jordan
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 13, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Pharmaceutical Research Unit, Jordan
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate
Details : Psilocin is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 13, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ELE-101, a novel, short-acting psychedelic compound which is intended to serve as a possible treatment for depression. ELE-101 was added to Beckley Psytech’s portfolio following the acquisition of Eleusis Therapeutics Limited in October 2022.
Lead Product(s): Psilocin,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 09, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ELE-101, a novel, short-acting psychedelic compound which is intended to serve as a possible treatment for depression. ELE-101 was added to Beckley Psytech’s portfolio following the acquisition of Eleusis Therapeutics Limited in October 2022.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 09, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The acquisition adds ELE-101, a next-generation, short-duration psychedelic ready for Phase 1 clinical trials, to Beckley Psytech’s pipeline. ELE-101 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin.
Lead Product(s): Psilocin,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Beckley Psytech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 24, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Beckley Psytech
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The acquisition adds ELE-101, a next-generation, short-duration psychedelic ready for Phase 1 clinical trials, to Beckley Psytech’s pipeline. ELE-101 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
October 24, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Psilocin, is a high-affinity agonist at serotonin 5HT2A receptors, which are especially prominent in the prefrontal cortex for the Treatment of Central Nervous System Disorders.
Lead Product(s): Psilocin,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Psilocin, is a high-affinity agonist at serotonin 5HT2A receptors, which are especially prominent in the prefrontal cortex for the Treatment of Central Nervous System Disorders.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 10, 2022

Details:
Psilocin is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Psilocin,Psilocybine
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Filament Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2022

Lead Product(s) : Psilocin,Psilocybine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Filament Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparing the Effects of Psilocin and Psilocybin in Healthy Adults
Details : Psilocin is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 08, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s active metabolite, both of which are critical for use in the medical setting.
Lead Product(s): Psilocin,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 06, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Details : The application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s active metabolite, both of which are critical for use in the medical setting.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 06, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Mindset has conducted several pharmacological tests on its proprietary synthesized compounds, including a gold-standard functional assay to determine its molecules' functional activity at the human 5HT-2A receptor and other serotonin subtypes.
Lead Product(s): Psilocin,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 31, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mindset has conducted several pharmacological tests on its proprietary synthesized compounds, including a gold-standard functional assay to determine its molecules' functional activity at the human 5HT-2A receptor and other serotonin subtypes.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 31, 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
14 Apr 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/biotechnology/lobe-sciences-ltd-announces-private-placement-to-support-drug-development-of-novel-co-1014272

20 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/20/2901566/0/en/atai-Life-Sciences-Announces-Update-on-Beckley-Psytech-s-Phase-1-2a-Trial-of-ELE-101-IV-Psilocin-for-Major-Depressive-Disorder-with-Initial-Results-from-Phase-1-and-First-Patients-.html

14 May 2024
// BUSINESSWIRE

29 Nov 2023
// PRESS RELEASE
https://phytonbiotech.com/phyton-controlled-substances-dealers-license-health-canada/

29 Oct 2023
// PRESS RELEASE
https://phytonbiotech.com/phyton-controlled-substances-dealers-license-health-canada/

24 Feb 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/terran-biosciences-announces-publication-of-pct-patent-application-covering-novel-orally-active-forms-of-psilocin-with-improved-pharmacokinetic-properties-301755108.html
Market Place
ABOUT THIS PAGE
66
PharmaCompass offers a list of Psilocin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Psilocin manufacturer or Psilocin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Psilocin manufacturer or Psilocin supplier.
PharmaCompass also assists you with knowing the Psilocin API Price utilized in the formulation of products. Psilocin API Price is not always fixed or binding as the Psilocin Price is obtained through a variety of data sources. The Psilocin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Psilocin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Psilocin, including repackagers and relabelers. The FDA regulates Psilocin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Psilocin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Psilocin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Psilocin supplier is an individual or a company that provides Psilocin active pharmaceutical ingredient (API) or Psilocin finished formulations upon request. The Psilocin suppliers may include Psilocin API manufacturers, exporters, distributors and traders.
click here to find a list of Psilocin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Psilocin DMF (Drug Master File) is a document detailing the whole manufacturing process of Psilocin active pharmaceutical ingredient (API) in detail. Different forms of Psilocin DMFs exist exist since differing nations have different regulations, such as Psilocin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Psilocin DMF submitted to regulatory agencies in the US is known as a USDMF. Psilocin USDMF includes data on Psilocin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Psilocin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Psilocin suppliers with USDMF on PharmaCompass.
Psilocin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Psilocin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Psilocin GMP manufacturer or Psilocin GMP API supplier for your needs.
A Psilocin CoA (Certificate of Analysis) is a formal document that attests to Psilocin's compliance with Psilocin specifications and serves as a tool for batch-level quality control.
Psilocin CoA mostly includes findings from lab analyses of a specific batch. For each Psilocin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Psilocin may be tested according to a variety of international standards, such as European Pharmacopoeia (Psilocin EP), Psilocin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Psilocin USP).